Alnylam Pharmaceuticals
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 2002-01-01
- Employees
- -
- Market Cap
- $35.9B
- Website
- http://www.alnylam.com/
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT05761301
- Locations
- π¨π¦
Clinical Trial Site, Toronto, Canada
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Transthyretin-Mediated Amyloidosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT05661916
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy
- Conditions
- Transthyretin-mediated Amyloidosis With CardiomyopathyATTR Amyloidosis With Cardiomyopathy
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Alnylam Pharmaceuticals
- Registration Number
- NCT05505838
- Locations
- πΊπΈ
Columbia University Irving Medical Center, New York, New York, United States
πΊπΈWashington University, Saint Louis, Missouri, United States
πΊπΈMayo Clinic Florida, Jacksonville, Florida, United States
A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT05256810
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05231785
- Locations
- π¬π§
Clinical Trial Site, Sheffield, United Kingdom
A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
Phase 2
Terminated
- Conditions
- Recurrent Calcium Oxalate Kidney Stone DiseaseElevated Urinary Oxalate Levels
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT05161936
- Locations
- π¬π§
Clinical Trial Site, Leeds, United Kingdom
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
Phase 2
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 672
- Registration Number
- NCT05103332
- Locations
- π¬π§
Clinical Trial Site, Torpoint, United Kingdom
πΊπΈClinical Trials Site, Beverly Hills, California, United States
πΊπΈClinical Trial site, Winston-Salem, North Carolina, United States
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Recruiting
- Conditions
- PolyneuropathyHereditary Transthyretin-mediated (hATTR) Amyloidosis
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT05040373
- Locations
- πͺπΈ
Clinical Trial Site, Madrid, Spain
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
Recruiting
- Conditions
- Primary Hyperoxaluria Type 1
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT04982393
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 394
- Registration Number
- NCT04936035
- Locations
- π¬π§
Clinical Trial Site, Manchester, United Kingdom